PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
US11359021B2 · kind B2 · utility
1Cited by
3References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 9, 2019 |
| Grant date | Jun 14, 2022 |
| Priority date | — |
| Expiry date | Apr 25, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A novel PD-L1 antibody, an antigen-binding fragment thereof, and a pharmaceutical use thereof. A humanized antibody comprising a CDR of the PD-L1 antibody, a pharmaceutical composition comprising the PD-L1 antibody and the antigen-binding fragment thereof and a use of the PD-L1 antibody as a drug. A use of a humanized PD-L1 antibody in preparing a drug for treating diseases or disorders associated with PD-L1.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.